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Aims To evaluate the safety and effectiveness of a compliant multi-electrode radiofrequency balloon catheter (RFB) used




This prospective, multicentre, single-arm study was conducted at six European sites and enrolled patients with
symptomatic paroxysmal atrial fibrillation. The primary effectiveness endpoint was entrance block in treated pul-
monary veins (PVs) after adenosine/isoproterenol challenge. The primary safety endpoint was the occurrence of
primary adverse events (PAEs) within 7 days. Cerebral magnetic resonance imaging and neurological assessments
were performed pre- and post-ablation in a subset of patients. Atrial arrhythmia recurrence was assessed over
12 months via transtelephonic and Holter monitoring. Quality of life was assessed by the Atrial Fibrillation Effect
on Quality of Life (AFEQT) questionnaire. Of 85 patients undergoing ablation per study protocol, PV entrance
block was achieved in all (one PV required touch-up with a focal catheter). Acute reconnection of >_1 PVs after
adenosine/isoproterenol challenge was observed in 9.3% (30/324) of PVs ablated. Post-ablation, silent cerebral
lesions were detected in 9.7% (3/31) of patients assessed, all of which was resolved at 1-month follow-up. One pa-
tient experienced a PAE (retroperitoneal bleed). Freedom from documented symptomatic and all arrhythmia was
72.2% and 65.8% at 12 months. Four patients (4.7%) underwent repeat ablation. Significant improvements in all
AFEQT subscale scores were seen at 6 and 12 months.
...................................................................................................................................................................................................
Conclusion PVI with the novel RFB demonstrated favourable safety and effectiveness, with low repeat ablation rate and clini-
cally meaningful improvement in quality of life.
...................................................................................................................................................................................................
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Introduction
Pulmonary vein isolation (PVI) with radiofrequency (RF) catheter ab-
lation is an effective treatment option for patients with paroxysmal
atrial fibrillation (PAF).1 Point-by-point RF ablation is a technically
challenging procedure, with a considerable learning curve required to
safely and effectively achieve PVI. Thus, balloon ablation catheters
have been developed with the aim of achieving PVI using fewer appli-
cations of ablation energy. The cryoballoon is the most commonly
used balloon ablation catheter, with others including the laser balloon
and RF balloon.1,2 However, since it is not possible to directionally ti-
trate energy circumferentially from their single ablative surface, the
varying thickness of the tissue at the pulmonary vein (PV) ostia means
What’s new?
• The novel multi-electrode radiofrequency balloon catheter
(RFB) consists of a compliant balloon with the ability to direc-
tionally tailor the dose of ablative energy simultaneously deliv-
ered along the balloon circumference.
• The prospective, multicentre SHINE study evaluated the safety
and effectiveness of the multi-electrode RFB when used with a
multi-electrode diagnostic catheter for pulmonary vein isolation
and electrophysiological mapping in 85 patients with symptom-
atic paroxysmal atrial fibrillation.
• The SHINE study demonstrated safe and effective use of the
multi-electrode circular diagnostic and RFB, with only one pri-
mary adverse event reported and sustained pulmonary vein en-
trance block achieved in all patients. At 12 months after ablation,
72.2% of the patients were free of documented symptomatic ar-
rhythmia recurrence and the patient cohort experienced signifi-
cant improvements in quality of life.
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that this could give rise to under- or over-ablation depending on tis-
sue thickness. Also, these balloon catheters are most often used
without electroanatomical mapping, potentially lengthening fluoros-
copy and/or procedure times.
The multi-electrode RF balloon catheter (RFB; HELIOSTAR,
Biosense Webster, CA, USA) is a 28-mm spherical diameter, compli-
ant balloon that is compatible with the three-dimensional electroana-
tomical mapping system (CARTOVR 3, Biosense Webster, CA,
USA).3,4 The RFB can perform circumferential or segmental ablation
with 10 irrigated, flexible gold electrodes, each capable of indepen-
dently delivering varying levels of RF energy to adjust for differences
in target tissues (Figure 1). The RADIANCE first-in-human study
established the feasibility of the RFB to achieve electrical PVI with a
favourable acute safety profile, without using a second focal cathe-
ter.3,4 However, the first generation RFB was limited by the inability
to monitor PV electrograms ‘online’ during RF energy delivery.
The multicentre SHINE study was designed to evaluate the safety
and effectiveness of the second-generation multi-electrode RFB in
combination with a multi-electrode diagnostic catheter for PV-
targeted ablation, with a post-procedure follow-up period of
12 months. A subgroup of patients was also screened for silent cere-
bral lesions (SCLs) using pre- and post-procedural diffusion-weighted
magnetic resonance imaging (MRI). The reproducibility of procedural
efficiency and clinical outcome were also evaluated under different
anaesthesia settings and across different centres.
Methods
Study design and patients
SHINE was a prospective, multicentre, single-arm clinical study evaluating
the safety and effectiveness of using the multi-electrode RFB in combina-
tion with the multi-electrode circular diagnostic catheter; electrophysio-
logical mapping of the atria (recording and stimulation) was facilitated
with the mapping system. The study was conducted at six sites in four
European countries in accordance with Good Clinical Practice
Guidelines and the principles of the Declaration of Helsinki. It was
reviewed and approved by ethics committees at all participating sites and
by all national authorities in participating countries.
Eligible patients had symptomatic PAF suitable for PVI and were able
to comply with uninterrupted anticoagulation. Exclusion criteria included
atrial fibrillation (AF) secondary to reversible or non-cardiac cause, previ-
ous ablation for AF, anticipation of receiving ablation other than PVI, and
persistent AF.
Atrial fibrillation ablation procedure
Following completion of the RADIANCE study,3,4 several modifications
were made to the ablation workflow for the SHINE study to further im-
prove device safety profile, namely eliminating dual transseptal access, bo-
lus dosing with heparin before transseptal puncture, maintaining activated
clotting time at 350–400 s, using an integrated 3-Fr diagnostic multi-
electrode circular catheter (LASSOSTAR, Biosense Webster, Irvine, CA,
USA) to minimise catheter exchange, continuously irrigating all side ports,
and using a target temperature setting of 55C.
Procedures were performed under conscious sedation or general an-
aesthesia. Computed tomography and/or magnetic resonance angiogra-
phy images were first reviewed to evaluate the number and size of the
PVs and left atrial anatomy. A single transseptal puncture was then per-
formed. Pre-ablation mapping and recording were conducted with either
the PENTARAYVR or the LASSOVR NAV catheters (Biosense Webster,
Irvine, CA, USA), and the electroanatomical mapping system, which was
then withdrawn from the left atrium. A multi-electrode oesophageal tem-
perature monitoring device was inserted before starting ablation; addi-
tional mechanical oesophageal deviation (DV8; Manual Surgical Sciences,
Inc.) was performed per physician’s preference. Target activated clotting
time was confirmed prior to insertion of the balloon catheter and main-
tained throughout the procedure. The RFB catheter with the intraluminal
circular diagnostic catheter was then introduced into the left atrium and
left in situ for the rest of the case. Tissue contact of the RFB was verified
through fluoroscopy, CARTO system visualisation of the balloon and bal-
loon size index, or by observing electrode impedance and temperature
parameters. During ablation, 15 W was simultaneously delivered to each
RFB electrode, and energy delivery to electrodes along the posterior wall
was typically stopped after 20 s or earlier in case of oesophageal tempera-
ture rise; posterior electrodes were identified by the balloon’s represen-
tation on the mapping system. The PV signals were monitored in real
time on the circular diagnostic catheter (Figure 2, Supplementary material
online, Video S1), and RF duration for the non-posterior wall-facing
Figure 1 The RFB and circular diagnostic catheter as visualised
using the electroanatomical mapping system. The RFB and the circu-
lar diagnostic catheter are shown at the ostium of LIPV during abla-
tion, where the bottom panel reflects the RF power being delivered
(yellow bar, 0–40 W), temperature measured (orange bar, 0–60
Celsius), starting impedance (dark green, 0–150 Ohms), and current
impedance (bright green, 0–150 Ohms) for each of the 10 individual
electrodes. The bottom panel also shows the posterior electrodes
#1–#3 are turned off. LIPV, left inferior pulmonary vein; LSPV, left
superior pulmonary vein; RF, radiofrequency; RFB, radiofrequency
balloon catheter; RIPV, right inferior pulmonary vein; RSPV, right su-
perior pulmonary vein.
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electrodes was limited to 60 s. Isolation of all targeted PVs was then con-
firmed with the circular catheter, or in some cases exchanged with the
Lasso Nav diagnostic catheter. Isoproterenol/adenosine challenge was
administered for all targeted PVs to confirm entrance block. There was
no minimum waiting period mandated after PVI was achieved.
Antiarrhythmic drug (AAD) therapy was managed per the institution’s
standard of care.
Rhythm monitoring on follow-up
Stringent arrhythmia monitoring included 24-h Holter monitors,
recorded at 6 and 12 months, and transtelephonic monitoring (TTM) at
1, 3, 6, and 12 months after ablation. In addition, patients were asked to
record and transmit their electrocardiogram (ECG) weekly though the
end of 5-month follow-up, and then monthly until the 12-month follow-up
visit. Patients were also asked to transmit any symptom-triggered ECG re-
cording that occurred throughout the study period. All TTM tracings and
Holter recordings were independently assessed by a core lab.
Study endpoints
The primary safety endpoint was the occurrence of primary adverse
events (PAEs) within 7 days following the initial ablation procedure.
Device- or procedure-related death, atrio-oesophageal fistula, and PV
stenosis occurring later than 7 days after the ablation procedure were
also considered as PAEs. Diaphragmatic paralysis/phrenic nerve palsy
were considered PAEs if symptoms had not resolved at the 3-month visit.
The primary effectiveness endpoint was acute procedural success, de-
fined as the confirmation of entrance block in treated PVs after adenosine
and/or isoproterenol challenge (with or without the use of a focal
catheter).
Secondary endpoints included any serious device adverse events; pro-
cedural characteristics; acute reconnection of >_1 PVs after adenosine/iso-
proterenol challenge; and symptomatic or asymptomatic recurrence of
AF (episodes > 30 s), atrial tachycardia (AT), and/or atrial flutter (AFL),
on/off AAD after a 3-month blanking period at 6- and 12 months. Total
procedure time was defined as the time of the first femoral puncture until
the time of the last catheter removal, meaning that the time needed for
transseptal mapping, ablation, and adenosine/isoproterenol was included.
Other procedural datapoints related to PVI were also analysed both by
subject and by vein.
Silent cerebral lesion assessment
Analyses of MRI data were performed in the neurological assessment
evaluable (NAE) analysis population. Incidences of SCLs were evaluated
using diffusion-weighted MRI at 72 h prior to the ablation procedure and
within 48 h post-procedure. Patients with identifiable lesions or neurolog-
ical symptoms had a follow-up MRI to determine lesion progress until the
lesions were resolved. Neurological and cognitive assessments were also
performed using the National Institutes of Health Stroke Scale (NIHSS).
Quality of life assessment
Patients completed the Atrial Fibrillation Effect on Quality of Life
(AFEQT) questionnaire at study baseline and at 3, 6, and 12 months after
ablation. The AFEQT questionnaire is an AF-specific health-related qual-
ity of life questionnaire, which includes 20 questions grouped into four
functional subscales, namely symptoms, daily activities, treatment con-
cern, and treatment satisfaction. Overall and subscale scores range from
0 to 100, with an overall score of 0 corresponding to complete disability,
while a score of 100 corresponds to no disability. For AFEQT scales, a
change of >_5 points has been identified as a benchmark for minimum clin-
ically important difference in an individual patient.5
Statistical analysis
The safety population comprised all enrolled patients who underwent in-
sertion of the study catheters. The per-protocol population included
patients who were enrolled and met all eligibility criteria, underwent RF
ablation with study catheters, and were treated for study-related
arrhythmia. The NAE population included patients from the per-protocol
Figure 2 (A) Voltage map of the left atrium and electrogram recorded by the circular diagnostic catheter (B) before, (C) during, and (D) after LSPV
isolation with the RFB. LSPV, left superior pulmonary vein; RFB, radiofrequency balloon; RIPV, right inferior pulmonary vein; RSPV, right superior pul-
monary vein.
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population who consented to and were eligible for the required
neurological assessments and had at least one post-ablation MRI scan.
Patient demographic, cardiovascular medical history, AAD history,
baseline CHA2DS2-VASc score, AF history, and procedure data were
summarised descriptively. The rate of PAEs and acute procedural success
were compared to a performance goal of 15% and 80%, respectively, by
using the exact test for a binomial proportion at a one-sided significance
level of 5%. If the one-sided 95% lower confidence bound for the primary
adverse event and effectiveness rates were greater than the performance
goals, the study was considered to have demonstrated safety and
effectiveness.
Secondary endpoint analyses were performed descriptively in the pro-
posed analysis populations, excluding the patients with missing outcomes.
Secondary effectiveness endpoints, including 6-month and 12-month ef-
fectiveness success, were summarised descriptively for patients in the
per-protocol population treating the endpoint as a binary variable, based
on available follow-up data. The point estimate and the one-sided 95%
exact binomial lower bound are presented. Time-to-event analyses were
also performed for these secondary effectiveness endpoints. Kaplan–
Meier curves and survival estimates were provided using data on all
patients in the per-protocol population. Patients who did not have effec-
tiveness failures but were followed up for durations shorter than the
endpoint-specified evaluation periods were censored at their last
observations.
Analysis of AFEQT overall and subscale scores were conducted in
the per-protocol population. Fisher’s exact test or the Kruskal–Wallis
test was used to compare differences in procedural data, primary ad-
verse event rate, and treatment success between patients treated
with conscious sedation compared with general anaesthesia.
Reproducibility of the 6-month and 12-month freedoms from AF/AT/
AFL across study sites was analysed using Fisher’s exact test. All sta-
tistical analyses were performed in SAS Studio 3.4 or SAS 9.4 (SAS
Institute Inc., Cary, NC, USA).
Results
Study population
The disposition of patients is shown in Supplementary material on-
line, Figure S1. Of the 98 (8 roll-in, 90 evaluable) patients enrolled in
the main study, 87 patients met the inclusion criteria, underwent the
ablation procedure, and were included in the safety population;
among these, 85 were included in the per-protocol populations after
the exclusion of two patients post-procedure who did not meet the
inclusion criteria. Baseline characteristics and medical history of the
patients in the safety population are shown in Table 1. Mean age was
60.2 years, mean CHA2DS2-VASc score was 1.4 ± 1.2, and mean left
atrial diameter was 38.5± 5.3 mm.
Procedural characteristics
The mean total procedure time was 87.6 min in the per-protocol
population, with a mean balloon dwell time of 40.3 min and a mean
total procedural fluoroscopy duration of 10.9 min (Table 2).
Procedures were performed under general anaesthesia in 54.0%
(46/85) of the cases. Procedure and fluoroscopy times were sig-
nificantly shorter for patients who received general anaesthesia
compared with conscious sedation (Table 3). Identification of
isolation was performed with the diagnostic catheter during RF
application or immediately after the full RF application. Real-time
electrogram analysis during ablation was possible in 79.0% (357/452)
of PVs. Nearly all (98.8%) patients and 99.7% of PVs were ablated with
only the RFB catheter. One patient required ablation with a focal RF
catheter to isolate the right inferior PV. Oesophageal temperature rise
occurred in 31.8% (27/85) of patients.
....................................................................................................................................................................................................................
Table 1 Baseline characteristics and medical history (safety population, N 5 87)
Safety population (N 5 87)
Age (years), mean (SD) 60.2 (10.05)
Men, n (%) 56 (64.4)
Time since AF diagnosis (months), mean (SD) 48.9 (51.26)
CHA2DS2-VASc score, mean (SD) 1.4 (1.23)
Left atrial diameter (mm), mean (SD) 38.5 (5.32)
Left ventricle ejection fraction (%), mean (SD) 61.1 (4.84)
Pharmacological cardioversion in the past 12 months, n (%) 8 (9.2)
Direct current cardioversion in the past 12 months, n (%) 4 (4.6)
Number of AADs failed, mean (SD) 1.3 (0.55)
Class I/III AADs, n (%) 50 (57.5)
Comorbidities, n (%)
Coronary artery disease 3 (3.4)
Congestive heart failure, NYHA Class I 1 (1.1)
Hypertension 42 (48.3)
Type II diabetes mellitus 8 (9.2)
Thromboembolic events 4 (4.6)
Atrial flutter 7 (8.0)
Obstructive sleep apnoea 1 (1.1)
AAD, antiarrhythmic drug; AF, atrial fibrillation; CHA2DS2-VASc, congestive heart failure, hypertension, age >_75 years, diabetes mellitus, stroke/transient ischaemic attack/
thromboembolism, vascular disease, age 65–74 years, sex category; NYHA, New York Heart Association; SD, standard deviation.
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Primary effectiveness and safety
endpoints
One (1.2%) patient experienced a PAE, with a one-sided 95% upper
confidence bound of 5.5%; therefore, the performance goal of 15%
was met. This PAE was a vascular access complication (retroperito-
neal bleed) during introduction of transseptal needle through the
sheath, which was treated conservatively, and the procedure was
completed. No deaths, atrio-oesophageal fistula, myocardial
infarction, stroke/cerebrovascular accident, transient ischaemic
attack, thromboembolism, PV stenosis, permanent phrenic nerve
paralysis, or cardiac tamponade/perforation were encountered
(Supplementary material online, Table S1). There were no serious de-
vice adverse events. One mild transient phrenic nerve palsy was ob-
served and resolved prior to discharge.
The primary effectiveness endpoint of sustained PV entrance
block was achieved for all (100%) patients; the one-sided 95%
lower confidence bound was 96.4%, above the performance goal
of 80%.
Subject- and vein-level PVI procedural data secondary effective-
ness endpoints are summarised in Table 4. Acute reconnection of >_
PVs after adenosine/isoproterenol challenge was observed in 22 out
of 82 (26.8%) patients, accounting for 30 out of 324 (9.3%) PVs ab-
lated. After the blanking period, four out of 85 (4.7%) patients under-
went repeat ablation. One patient was ablated for typical AFL (so the
PVs were not remapped), while three were treated due to AF sec-
ondary to reconnection affecting >_1 PV: left superior PV (n = 1), right
superior PV (n = 1), right inferior PV (n = 1), left inferior PV (n = 1),
and common left PV (n = 1).
....................................................................................................................................................................................................................
Table 2 General ablation procedural characteristics (per-protocol population, N 5 85)
Per-protocol population (N 5 85)
Total procedure time (min), mean (SD) 87.6 (22.3)
Balloon dwell time (min), mean (SD) 40.3 (16.7)
Total duration of RF applications (min), mean (SD) 6.1 (2.4)
Total fluoroscopy duration (min), mean (SD) 10.9 (9.1)
Fluoroscopy time during balloon phase (min), mean (SD) 7.4 (7.2)
Fluid delivered via study catheter (mL), mean (SD) 993.4 (409.9)
Total mapping time (min), mean (SD) 6.8 (4.7)
General anaesthesia, n/N (%) 46/85 (54.0)






LPV (common, %) 76.4
Single-shot isolation (%) 73.9
EGM, electrogram; LIPV, left inferior pulmonary vein; LPV, left pulmonary vein; LSPV, left superior pulmonary vein; PV, pulmonary vein; RF, radiofrequency; RIPV, right inferior
pulmonary vein; RMPV, right middle pulmonary vein; RSPV, right superior pulmonary vein; SD, standard deviation.
....................................................................................................................................................................................................................
Table 3 Procedural efficiency data, safety, and treatment outcome in patients receiving RF ablation under general an-
aesthesia vs. conscious sedation (per-protocol population, N 5 85)
General anaesthesia (N 5 46) Conscious sedation (N 5 39) P-value
Mapping time (min), mean (SD) 7.9 (5.6) 5.5 (3.0) 0.06
Balloon dwell time (min), mean (SD) 36.8 (12.9) 44.5 (19.7) 0.06
Fluoroscopy time (min), mean (SD) 5.9 (4.8) 16.7 (9.6) <0.001
Procedure time (min), mean (SD) 81.8 (19.4) 94.4 (23.7) 0.008
Acute effectiveness, n/N (%) 45/45 (100) 37/37 (100) NA
Primary adverse event, n/N (%) 0/39 1/45 (2.2) 1.00
6-month freedom from symptomatic AF/AT/AFL recurrences, n/N (%) 38/45 (84.4) 30/39 (76.9) 0.42
12-month freedom from symptomatic AF/AT/AFL recurrences, n/N (%) 31/41 (75.6) 26/38 (68.4) 0.62
AF, atrial fibrillation; AFL, atrial flutter; AT, atrial tachycardia; RF, radiofrequency; SD, standard deviation.
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Subclinical lesion on MRI and
neurological evaluation
Post-procedure, three of the 31 (9.7%) patients who were assessed
had a new SCL detected. One of these occurred in a patient who did
not meet the study inclusion criteria (age >75 years). All SCLs were
resolved subsequently (i.e. two patients at 1 month and one patient
at 10 months—the first repeat MRI obtained).
NIHSS scores are summarised in Supplementary material online,
Table S2. There were no cases of clinical stroke; one patient devel-
oped limb ataxia, adjudicated as related to stress and fatigue by both
the on-site and clinical event committee neurologists.
Six- and 12-month effectiveness
outcomes and reproducibility
The success rate, defined as freedom from documented symptomatic
AF/AT/AFL recurrences, was 81.0% (68/84) at 6 months and 72.2%
(57/79) at 12 months, and 65.8% (52/79) for all (symptomatic or
asymptomatic) documented atrial arrhythmia recurrence at
12 months (binomial analyses). The outcomes were similar in patients
who received ablation under general anaesthesia or conscious seda-
tion (Table 3). The Kaplan–Meier estimate of probability of freedom
from documented symptomatic atrial arrhythmia recurrence was








Table 4 Subject- and vein-level PVI procedural data
Acute reconnection n/N (%)
Patients 22/82 (26.8)






LPV (common) 2/8 (25.0)
Focal catheter ablation for PV isolation Ablated by balloon catheter only, n/N (%) Ablated by balloon catheter and focal catheter, n/N (%)
Patients 84/85 (98.8) 1/85 (1.2)
PVs, overall 326/327 (99.7) 1/327 (0.3)
LIPV 75/75 (100) 0/75
LSPV 76/76 (100) 0/76
RIPV 82/83 (98.8) 1/83 (1.2)
RSPV 83/83 (100) 0/83
RMPV 1/1 (100) 0/1
LPV (common) 9/9 (100) 0/9
Time to PV isolation by real-time EGMa Mean (SD) (s)






LPV (common) 18.0 (17.3)






LPV (common) 3.4 (1.3)
LIPV, left inferior pulmonary vein; LPV, left pulmonary vein; LSPV, left superior pulmonary vein; PV, pulmonary vein; RF, radiofrequency; RIPV, right inferior pulmonary vein;
RMPV, right middle pulmonary vein; RSPV, right superior pulmonary vein; SD, standard deviation; NA, not applicable.
aLIPV, left inferior pulmonary vein; LPV, left pulmonary vein; LSPV, left superior pulmonary vein; PV, pulmonary vein; RIPV, right inferior pulmonary vein; RMPV, right middle pul-
monary vein; RSPV, right superior pulmonary vein.
bLIPV, n = 74; LSPV, n = 75; RIPV, n = 80; RSPV, n = 80; RMPV, n = 1; LPV (common), n = 7.
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73.8%) and 69.4% at 12 months (one-sided 95% lower confidence
bound of 60.9%; Figure 3). At 12 months, 38.0% (30/79) of patients
were in use of Class I/III AADs, corresponding to a 32.8% decrease in
AAD use compared to baseline.
Recurrence rates were reproducible at 6 and 12 months across
study centres (Supplementary material online, Figure S2A and B). No
statistical difference was detected between sites for 6- or 12-month
recurrence (P = 0.210 and 0.779, respectively).
Quality of life
Patients in the per-protocol population showed substantial improve-
ment in quality of life scores in all subscale categories at 12 months af-
ter ablation (Figure 4). Specifically, patients scored an average of 27.1
points higher on the overall AFEQT score at 12 months post-
ablation than they did pre-ablation. Gains ranging from 18.5 to 33.0
points, on average, were realised among individual subscores. Mean
AFEQT improvements exceeded the universally accepted clinically
important differences (þ5 points) from 6 to 12 months.
Discussion
The SHINE study demonstrated the safe and effective use of the
multi-electrode circular diagnostic and RFB catheter when used for
electrophysiological mapping and RF ablation during treatment of
PAF through PVI. The findings from the RADIANCE study were ex-
panded in SHINE to a wider patient cohort treated by more early
users of the RFB catheter, with clinical outcome at 1-year follow-up.
Importantly, 99.7% of the ablated veins (all except for one vein)
could be isolated with a single RFB catheter, without the need for
touch-up with a focal catheter. With the circular diagnostic catheter,
real-time electrogram analysis was possible in nearly 80% of cases.
The most common reason for failure of real-time monitoring was
noise on the circular diagnostic catheter because of its proximity to
one or more active RF electrodes on the RF balloon. The acute
reconnection rate after adenosine challenge was 9% of PVs in the
current study. All reconnections were targeted by further ablation
and persistent isolation after pharmacological challenge was demon-
strated in all patients. With a rather stringent arrhythmia monitoring
method, 72.2% of patients in the SHINE study were free of docu-
mented symptomatic left atrial arrhythmia at 12 months after abla-
tion, and 65.8% including asymptomatic recurrence. These results are
comparable with those obtained in early experience of point-by-
point RF (contact force or non-contact force) ablation or cryoabla-
tion studies.6–8 The long-term success is likely to improve over time
with more experience and wider adoption, as has been observed
with focal RF and cryoablations.9–11 More recently, pulsed field abla-
tion technology has become available. Early results of PAF ablation
with 81 patients showed a 12-month freedom from atrial arrhythmia
recurrence of over 80%; however, the majority of the patients re-
ceived a protocol-mandated remap and reablation (if reconnection
occurred) at 75 days which may have helped optimised long-term
effectiveness.12
There was no significant variation on freedom from arrhythmia re-
currence at 6 and 12 months among the study sites, suggesting repro-
ducibility across sites, most likely due to the simplistic and
standardised nature of the ablation workflow with the RFB catheter.
This is supported by the short procedure times, balloon dwell times,
and fluoroscopy times observed in our study. In general, balloon abla-
tion systems appear to have shorter learning curves and greater re-
producibility compared with point-by-point RF ablation.13 PVI with
the RFB catheter yielded comparable safety and 1-year treatment
outcomes under general anaesthesia and conscious sedation, with
shorter procedure and fluoroscopy times under general anaesthesia.
The ability to consistently achieve PVI in a short, predictable time
with a single catheter may have significant economic impact on the
healthcare system in terms of cost saving. This will need to be exam-
ined in future studies.
Only one patient in the SHINE study experienced a PAE (a retro-
peritoneal bleed that was treated conservatively). There were no
Figure 3 Kaplan–Meier analysis of 6- and 12-month effectiveness endpoint, time to first documented symptomatic effectiveness failure (per-proto-
col population, N = 85). AF, atrial fibrillation; AFL, atrial flutter; AT, atrial tachycardia.
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incidences of sustained phrenic nerve palsy, as the ability to pace
from the individual electrodes on the RFB offers another point of
confirmation of proximity to the phrenic nerve to avoid phrenic
nerve injury, although this was not routinely done during the study.
Also, the customisable energy delivery across different electrodes
allows minimisation of ablation on the posterior wall; with the reduc-
tion in maximum RF duration from 30 to 20 s compared to the
RADIANCE study,4 SHINE showed a reduction in the incidence of
oesophageal temperature rise as well. SCL is a known complication
after invasive cardiac procedures, although its relevance to clinical
stroke and long-term neurological impact are unclear at this time.14
SCL rates of up to 40% have been reported following AF ablation,
although detection rates vary depending on ablation method, proce-
dural workflow, and lesion detection method.15–17 Diffusion-
weighted MRI, as used in the SHINE study, provides a method for the
detection of small, clinically silent embolic lesions with high sensitivity.18
A low incidence of SCLs was observed in the current study, with 3
(9.7%) patients showing asymptomatic lesions following ablation, which
had all resolved at a follow-up MRI. In the previously published
RADIANCE study, 23% of patients showed new SCLs on their pre-
discharge MRI, all of which resolved at follow-up.4,19 These results sug-
gest that modifications to the ablation workflow between the
RADIANCE and SHINE studies may have contributed to a lower inci-
dence of SCL.
AF has a detrimental effect on many aspects of quality of life,20 and
the primary goal of AF ablation is to improve quality of life through
the elimination of arrhythmia-related symptoms, such as palpitations,
fatigue, or effort intolerance.1 Traditional clinical study outcomes such
as freedom from atrial arrhythmia recurrence may not necessarily
correlate with patients’ perception of quality of life recovery. For
example, in the SMART-AF study, patients reported improvement in
physical and mental components of quality of life following RF ablation,
irrespective of effectiveness outcomes.7 Thus, formal assessment of
quality of life has an increasingly important role in the evaluation of
novel ablation procedures.1 In the current study, quality of life as eval-
uated through the AFEQT questionnaire showed significant benefits
in patients’ health-related quality of life and satisfaction with AF con-
trol and symptoms as a consequence of the ablation treatment. More
patients in this study had AF recurrence documented than those who
required repeat AF ablation, probably because their AF recurrences
were infrequent and/or did not represent a significant enough symp-
tomatic burden to justify further treatment. An improvement of ap-
proximately 20 points in total AFEQT score, as observed in this study,
has previously been shown to correlate with improvement on the
Patient Global Change assessment.19 This improvement in AFEQT
score was also accompanied with a 33% reduction in the Class I/III
AAD usage at 12 months compared to baseline.
Limitations
This was a single-arm, non-randomised clinical study, and all cases
were performed by operators well experienced with other single-
shot PVI devices. Larger studies are needed to evaluate the generalis-
ability of these study results. All cases were performed with oesopha-
geal temperature monitoring and a subset with mechanical
oesophageal deviation, and our results may not be applicable to cases
performed without. As the definition of success rates and failure
modes vary among registration studies, a randomised controlled
study is required to draw direct comparisons of the clinical efficacy
with other AF ablation technologies.
Conclusion
In this multicentre study, PVI with the novel RFB catheter demon-
strated favourable safety and clinical effectiveness at a 12-month
follow-up, with a low repeat ablation rate and clinically meaningful
improvement in quality of life.
Supplementary material
Supplementary material is available at Europace online.
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